Hong Kong
· Delayed Price · Currency is HKD HBM Holdings Company Description
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.
It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats.
The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm.
It is also developing HBM7020 for treating hematologic carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM1022, HBM9014, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors.
The company was incorporated in 2016 and is based in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Jingsong Wang |
Contact Details
Address: Building A3 Suzhou, 215123 China | |
| Phone | 86 512 6579 0025 |
| Website | harbourbiomed.com |
Stock Details
| Ticker Symbol | 2142 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | KYG4403H1002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jingsong Wang M.D., Ph.D. | Founder, Chairman and Chief Executive Officer |
| Dr. Yiping Rong Ph.D. | Chief Scientific Officer and Executive Director |
| Youchen Chen | Vice President, Chief Financial Officer and Investor Relations |
| Dr. Ian Y. Liu | Senior Vice President and Global Head of Legal and Joint Company Secretary |
| Dr. Peter F. Moesta Ph.D. | Member of Scientific Advisory Board and Chief CMC Advisor |
| Dr. Xiaolu Tao | Chief Development Officer |
| Dr. Steve Arkinstall DPhil | Chief Scientific Advisor |
| Dr. Ben Chih Ph.D. | Chief Scientific Officer of Neurosciences - Harbour BioMed US |
| Dr. Raymond S. Zheng Ph.D. | Chief Business Officer |
| Michael D. Patten | Chief Strategy Officer and Head of Global Alliance |